C 型肝炎病毒的感染在全世界影響了約一億七千萬人。在台灣，C 型肝炎的盛 行率約為 2-5%，但在某些區域可高到 20-60%。C 型肝炎的治療目前以長效型干擾素（pegylated interferon）與 ribavirin 的合併使用為主，治療時間的長短可以基因型來調整。
本研究採取回溯性病歷回顧的方式，自 2002  年 1 月 1 日起至 2005年 12 月 31日止，收集三家區域教學醫院的門診病患，診斷為 C 型肝炎並且以 peginterferon alfa 2b 及 ribavirin 合併治療處方者。 針對治療成功與否因素分析，僅對年齡及病毒基因型具有相關性（P < 0.05），與性別、體重都沒有相關性（P > 0.05）。檢驗值異常出現亦無法判定與 peginterferon alfa  2b 或是  ribavirin 使用的劑量是否有關聯性。

Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The  duration of treatment may  be individualized by the genotype.
Data  was  collected from  an outpatient computerized prescription data base of three regional hospitals from January 1, 2002, through December 31,  2005. Patients who were diagnosed as hepatitis C and were treated by combination of peginterferon alfa 2b and ribavirin were  included.
The response of treatment is related to age and the genotype of hepatitis C virus  (P<  0.05), but  not  related to  gender and  weight (P  >  0.05). We can not conclude if the occurrences of abnormal laboratory data are related to the dosage of peginterferon alfa 2b and  ribavirin.